All In Biotech

Drug Trial Radar · NCT06707987

Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)

An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke (FORPI Registry)

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23,250

Actual

Start

Mar 1, 2021

Primary completion

Dec 31, 2024

Study completion Feb 1, 2025

Sponsor

Lead sponsor
Supergene, LLCIndustry
Sponsor type
Industry
Collaborators
Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Non-immunogenic staphylokinaseDrug

    Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS) score of 0-2 on day 90 after drug administrationTime frame: day 90 after drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Federal Brain and Neurotechnology Center

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.